Literature DB >> 32061098

On the empirical choice of the time window for restricted mean survival time.

Lu Tian1, Hua Jin2, Hajime Uno3, Ying Lu1, Bo Huang4, Keaven M Anderson5, L J Wei6.   

Abstract

The t-year mean survival or restricted mean survival time (RMST) has been used as an appealing summary of the survival distribution within a time window [0, t]. RMST is the patient's life expectancy until time t and can be estimated nonparametrically by the area under the Kaplan-Meier curve up to t. In a comparative study, the difference or ratio of two RMSTs has been utilized to quantify the between-group-difference as a clinically interpretable alternative summary to the hazard ratio. The choice of the time window [0, t] may be prespecified at the design stage of the study based on clinical considerations. On the other hand, after the survival data have been collected, the choice of time point t could be data-dependent. The standard inferential procedures for the corresponding RMST, which is also data-dependent, ignore this subtle yet important issue. In this paper, we clarify how to make inference about a random "parameter." Moreover, we demonstrate that under a rather mild condition on the censoring distribution, one can make inference about the RMST up to t, where t is less than or even equal to the largest follow-up time (either observed or censored) in the study. This finding reduces the subjectivity of the choice of t empirically. The proposal is illustrated with the survival data from a primary biliary cirrhosis study, and its finite sample properties are investigated via an extensive simulation study.
© 2020 The International Biometric Society.

Entities:  

Keywords:  Kaplan-Meier estimator; RMST; hazard ratio; logrank test

Mesh:

Year:  2020        PMID: 32061098      PMCID: PMC8687138          DOI: 10.1111/biom.13237

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  15 in total

1.  The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice.

Authors:  J O IRWIN
Journal:  J Hyg (Lond)       Date:  1949-06

2.  Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.

Authors:  Hajime Uno; Brian Claggett; Lu Tian; Eisuke Inoue; Paul Gallo; Toshio Miyata; Deborah Schrag; Masahiro Takeuchi; Yoshiaki Uyama; Lihui Zhao; Hicham Skali; Scott Solomon; Susanna Jacobus; Michael Hughes; Milton Packer; Lee-Jen Wei
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

3.  Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.

Authors:  Bo Huang; Pei-Fen Kuan
Journal:  Pharm Stat       Date:  2017-12-28       Impact factor: 1.894

4.  Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.

Authors:  Shufang Liu; Chenghao Chu; Alan Rong
Journal:  Pharm Stat       Date:  2018-07-29       Impact factor: 1.894

5.  Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations.

Authors:  Lu Tian; Haoda Fu; Stephen J Ruberg; Hajime Uno; Lee-Jen Wei
Journal:  Biometrics       Date:  2017-09-12       Impact factor: 2.571

6.  Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.

Authors:  Lihui Zhao; Lu Tian; Hajime Uno; Scott D Solomon; Marc A Pfeffer; Jerald S Schindler; Lee Jen Wei
Journal:  Clin Trials       Date:  2012-08-22       Impact factor: 2.486

7.  Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification.

Authors:  J M Lachin; M A Foulkes
Journal:  Biometrics       Date:  1986-09       Impact factor: 2.571

8.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

Authors:  S Vincent Rajkumar; Susanna Jacobus; Natalie S Callander; Rafael Fonseca; David H Vesole; Michael E Williams; Rafat Abonour; David S Siegel; Michael Katz; Philip R Greipp
Journal:  Lancet Oncol       Date:  2009-10-21       Impact factor: 41.316

9.  Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.

Authors:  Hajime Uno; Janet Wittes; Haoda Fu; Scott D Solomon; Brian Claggett; Lu Tian; Tianxi Cai; Marc A Pfeffer; Scott R Evans; Lee-Jen Wei
Journal:  Ann Intern Med       Date:  2015-07-21       Impact factor: 25.391

Review 10.  Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.

Authors:  Ludovic Trinquart; Justine Jacot; Sarah C Conner; Raphaël Porcher
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

View more
  11 in total

1.  The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring.

Authors:  Gaohong Dong; Lu Mao; Bo Huang; Margaret Gamalo-Siebers; Jiuzhou Wang; GuangLei Yu; David C Hoaglin
Journal:  J Biopharm Stat       Date:  2020-06-17       Impact factor: 1.051

2.  Stratified Restricted Mean Survival Time Model for Marginal Causal Effect in Observational Survival Data.

Authors:  Ai Ni; Zihan Lin; Bo Lu
Journal:  Ann Epidemiol       Date:  2021-10-04       Impact factor: 3.797

3.  Implementation of an Alternative Method for Assessing Competing Risks: Restricted Mean Time Lost.

Authors:  Hongji Wu; Hao Yuan; Zijing Yang; Yawen Hou; Zheng Chen
Journal:  Am J Epidemiol       Date:  2022-01-01       Impact factor: 5.363

Review 4.  Quantifying treatment differences in confirmatory trials under non-proportional hazards.

Authors:  José L Jiménez
Journal:  J Appl Stat       Date:  2020-09-03       Impact factor: 1.416

5.  Are restricted mean survival time methods especially useful for noninferiority trials?

Authors:  Boris Freidlin; Chen Hu; Edward L Korn
Journal:  Clin Trials       Date:  2021-02-24       Impact factor: 2.486

6.  Statistical Considerations for Sequential Analysis of the Restricted Mean Survival Time for Randomized Clinical Trials.

Authors:  Ying Lu; Lu Tian
Journal:  Stat Biopharm Res       Date:  2020-10-09       Impact factor: 1.452

7.  On restricted mean time in favor of treatment.

Authors:  Lu Mao
Journal:  Biometrics       Date:  2021-09-25       Impact factor: 2.571

Review 8.  Which test for crossing survival curves? A user's guideline.

Authors:  Ina Dormuth; Tiantian Liu; Jin Xu; Menggang Yu; Markus Pauly; Marc Ditzhaus
Journal:  BMC Med Res Methodol       Date:  2022-01-30       Impact factor: 4.615

9.  Estimation and modeling of the restricted mean time lost in the presence of competing risks.

Authors:  Sarah C Conner; Ludovic Trinquart
Journal:  Stat Med       Date:  2021-02-10       Impact factor: 2.373

10.  Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials.

Authors:  Chen Hu; Meihua Wang; Cai Wu; Heng Zhou; Cong Chen; Scott Diede
Journal:  JAMA Netw Open       Date:  2021-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.